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Abstract
Background: CD8
+ cytotoxic T lymphocytes (CTLs) are crucial for eliminating hepatitis B virus (HBV) infected cells. DNA
vaccination, a novel therapeutic strategy for chronic virus infection, has been shown to induce CTL responses. However,
accumulated data have shown that CTLs could not be effectively induced by HBV DNA vaccination.
Methodology/Principal Findings: Here, we report that praziquantel (PZQ), an anti-schistoma drug, could act as an adjuvant
to overcome the lack of potent CTL responses by HBV DNA vaccination in mice. PZQ in combination with HBV DNA
vaccination augmented the induction of CD8
+ T cell-dependent and HBV-specific delayed hypersensitivity responses (DTH)
in C57BL/6 mice. Furthermore, the induced CD8
+ T cells consisted of both Tc1 and Tc17 subtypes. By using IFN-c knockout
(KO) mice and IL-17 KO mice, both cytokines were found to be involved in the DTH. The relevance of these findings to HBV
immunization was established in HBsAg transgenic mice, in which PZQ also augmented the induction of HBV-specific Tc1
and Tc17 cells and resulted in reduction of HBsAg positive hepatocytes. Adoptive transfer experiments further showed that
PZQ-primed CD8
+ T cells from wild type mice, but not the counterpart from IFN-c KO or IL-17 KO mice, resulted in
elimination of HBsAg positive hepatocytes.
Conclusions/Significance: Our results suggest that PZQ is an effective adjuvant to facilitate Tc1 and Tc17 responses to HBV
DNA vaccination, inducing broad CD8
+ T cell-based immunotherapy that breaks tolerance to HBsAg.
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Introduction
Chronic viral hepatitis B, a disease caused by hepatitis B virus
(HBV), is a worldwide health problem [1,2,3]. The host immune
response plays a key role in the outcome of HBV infection [4,5,6].
Efficient induction of multi-specific CD8
+ T cell responses against the
core and surface antigens of this virus can control HBV infections
[7,8,9]. Particularly, reports have described the involvement of two
main subsets of CD8
+ Tc e l l s ,t h eI F N - c-producing Tc1 cells [10,11]
and IL-17-secreting Tc17 cells [12,13,14]. It becomes increasingly
clear that efficient expansion of virus-specific Tc1 cells resolves HBV
infection by cytolytic and noncytolytic mechanisms [15,16,17],
although the mechanism of action by Tc17 cells remains unclear.
HBV DNA immunization is a promising strategy for inducing
strong CD8
+ T cell-mediated immunity in mice [18,19,20,21],
whereas this effect has been only transient and weak in clinical
trials [22,23]. To move beyond various approaches already
employed to improve DNA vaccination, we have explored the
use of novel adjuvants that would specifically potentiate the Tc1
and/or Tc17 type of T cells as a means to overcome the problem.
Praziquantel (PZQ) has been used for the treatment of Schistoma
japonicum infection without severe side effects [24]. It has been
found that the humoral and cellular immune responses of the host
were enhanced after being treated with this drug [25,26]. We
recently demonstrated that PZQ could act as an adjuvant to
enhance cellular responses to HBsAg DNA vaccination in mice
[27]. However, it was not clear how PZQ affected CD8
+ T cell
responses and whether the effect of PZQ was strong enough to
break immune tolerance in HBsAg-transgenic mice. We have
begun to address these questions in the present report.
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PZQ enhanced CD8
+ T cell-mediated responses to HBV
DNA vaccine
Delayed-type hypersensitivity (DTH) is a well-established
readout for T cell responses to vaccination [28,29]. To determine
the immunogenic effect of PZQ on HBV DNA vaccination, DTH
responses from C57BL/6 mice immunized with pcD-S2 in the
presence or absence of PZQ were compared. Using HBsAg as a
rechallenging antigen, we found that PZQ augmented the DTH
response to HBsAg (Fig. 1A).
To further determine the subpopulations of T cell in the
augmented DTH, over 90% of either CD4
+ or CD8
+ T cells were
depleted with anti-CD4 or anti-CD8 mAbs respectively (Fig. 1B).
Interestingly, the depletion of CD8
+ T cells significantly blunted
DTH, whereas the depletion of CD4
+ T cells had little impact
(Fig. 1C–D), suggesting that PZQ preferentially augmented CD8
+
T cell responses to pcD-S2 vaccination.
Induction of Tc1 and Tc17 cells during DNA vaccination
with PZQ
Effector cytotoxic CD8
+ T cells can be divided into IFN-c-
producing (Tc1) and IL-17-producing (Tc17) subtypes [10,11,12],
both of which might be involved in DTH [30,31,32,33,34]. To
delineate which was induced by PZQ, we isolated splenic cells from
mice immunized with pcD-S2, pcD-S2 plus vehicle, or pcD-S2 plus
PZQ and restimulated the cells in vitro with an HBsAg-derived
peptide, S208-215. The CD8
+ T cells from mice immunized with
pcD-S2 and PZQ secreted both IFN-c and IL-17 at a higher level
than those of the controls (Fig. 2A–C), suggesting PZQ induced
both Tc1 and Tc17 subtypes. To identify the cytokine-producing
cells, restimulated CD8
+ T cells were intracellularly stained with
anti-IL-17 and IFN-c mAbs and examined by flow cytometry. As
expected, many IFN-c single-positive (Tc1) and IL-17 single-
positive were observed (Tc17), but very few IFN-c and IL-17
double-positive, CD8
+ T cells were shown (Fig. 2D).
Figure 1. Induction of DTH was mediated by CD8
+ T cells in pcD-S2 and PZQ immunized group. A: Twelve days after the second
immunization with indicated the combinations, all groups were challenged with the rHBsAg in the right foot pad as test and with a saline solution in
the left foot pad as control. The thickness of footpads was measured at 24, 48 and 72 h. B, Mice were depleted of CD4
+ (CD4del) or CD8
+ (CD8del) T
cells by in vivo injection of specific mAbs. The efficiency of depletion was determined by flow cytometry of splenocytes. The numbers indicate the
percentages of CD4
+ or CD8
+ T cells. C: Ten days after the second immunization of pcD-S2 plus PZQ, mice were injected i.p. with anti-CD4 mAb, anti-
CD8 mAb, or rat IgG and challenged 2 days later with rHBsAg. DTH was measured at 24 h. D: The immunization schedule is shown. The data shown
summarizes one of three experiments, all of which demonstrated similar results (* p,0.05; ** p,0.01).
doi:10.1371/journal.pone.0025525.g001
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necessary for the augmented HBsAg-specific DTH, pcD-S2
immunization was carried out in IFN-c KO mice and IL-17
KO mice. Compared to that of wild-type mice, DTH was
significantly decreased in the IFN-c KO or IL-17KO mice (Fig. 3A
and 3B). Taken together, PZQ was shown to facilitate both Tc1
and Tc17 cells.
PZQ broke tolerance to HBsAg in HBsAg-transgenic mice
To test if PZQ-induced Tc1 and Tc17 cells in vivo had a
potential to clear tolerized viral antigens, HBsAg-Tg mice were
immunized with pcD-S2 in the presence and absence of PZQ. We
observed that PZQ also increased the levels of Tc1 and Tc17 cells
and the HBsAg-specific DTH in these animals (Fig. 4A and 4B).
To assess the possible therapeutic effects, we examined lymphocyte
infiltration in the liver of immunized HBsAg-Tg mice. As shown in
Fig. 5A, no infiltration was detected in nontreated mice. The
highest level of infiltration was noted in mice immunized with
pcD-S2 and PZQ, as compared to mice immunized with pcD-S2
alone or with vehicle. In addition, the PZQ-treated DNA vaccine
group was the only group showing a significant number of CD8
+ T
cells in the infiltrates, presumably of the Tc1 and Tc17 subtypes
(Fig. 5A). No CD4
+ T cells were detected (data not shown) in this
group. Lastly, no obvious change in liver morphology was noted in
this group, suggesting that the induced CD8
+ T cells were not
overtly pathogenic.
Consistent with the observed CD8
+ T cell infiltration, a
significant reduction of HBsAg-positive hepatocytes following
immunizations with pcD-S2 plus PZQ was observed (Fig. 5A
and 5B). However, the level of HBsAg in the blood was not
significantly changed (Fig. 5C).
The reduction of HBsAg-positive hepatocytes was likely due to
killing of these cells by the infiltrating CD8
+ T cells. To confirm
this, serum ALT levels were analyzed on weeks 0, 1, 2, 3, and 4
after the final immunization. As depicted in Fig. 5D, serum ALT
reached the highest level on week 1 and gradually declined to a
basal level on week 4 in mice immunized with pcD-S2 plus PZQ.
In contrast, ALT levels remained low throughout the same period
in control mice immunized with pcD-S2 alone and pcD-S2 plus
vehicle (Fig. 5D). This result thus supported our speculation.
Figure 2. Tc1 and Tc17 cells induction in response to HBsAg DNA vaccination with PZQ. A–B, Splenic T cells were isolated on day 14 after
the third immunization and were stimulated with the HBsAg-derived peptide S208-215 in the presence of brefeldin A (5 mg/ml) for 6 h in culture and
immunostained for surface CD8, and intracellular IFN-c and IL-17. C, Summary of the percentage of IFN-c- and IL-17-expressing CD8
+ T cells. D,
Intracellular staining for IFN-c and IL-17 in CD8
+ T cells. C57BL/6 mice were immunized with pcD-S2 and PZQ and CD8
+ T cells isolated on day 7 after
third immunization were stimulated in vitro. Data shown are representative of 3 independent experiments (* p,0.05; ** p,0.01).
doi:10.1371/journal.pone.0025525.g002
PZQ Primes Tc1 and Tc17
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25525PZQ-induced cytolytic CD8
+ T cells are effectors in killing
of HBsAg-positive hepatocytes
In order tofurther identifythe particular role ofTc1 and Tc17 cells
in elimination of HBsAg-positive hepatocytes, C57BL/6 wild type,
IFN-c KO, or IL-17 KO mice were immunized with pcD-S2 and
PZQ, followed by analysis of HBsAg specific CD8
+ T cell-mediated
killings in vivo. As expected, the highestpercentage of antigen-specific
killing (,60%) was noted in immunized wild type mice, as compared
to that in IFN-c KO (,30%) or IL-17 KO (,35%) mice (Fig. 6A–B).
This result demonstrated that both Tc1 and Tc17 cells were involved
in the elimination of HBsAg positive hepatocytes.
To establish the role of these CD8
+ T cells as the effectors for
killing of HBsAg-positive hepatocytes, CD8
+ T cells were isolated
from immunized mice and purified to 90–95% purity on day 7
after the final immunization, and adoptively transferred intrave-
nously into normal HBsAg-Tg mice at 5610
6 cells per recipient
animal. Only the transfer of CD8
+ T cells from the wild type mice
could significantly reduce HBsAg expression in the liver of the
recipients, whereas CD8
+ T cells from the IFN-c KO or IL-17
KO mice were not effective (Fig. 6C–D). Consistently, the ALT
level rose after adoptive transfer of the wild type CD8
+ T cells and
returned to a normal level on week 2 post transfer (Fig. 6E). These
results thus established that both Tc1 and Tc17 cells were the
effectors.
Discussion
HBV-specific CD8
+ T cells with killing of HBV-infected
hepatocytes is the most desirable option for the control of chronic
HBV infection [35]. In this report, we find the anti-Schistosoma
drug praziquantel (PZQ) to be highly effective at eliciting Tc1 and
Tc17 responses in both wild type (WT) and HBsAg-Tg mice.
Importantly, the induced HBsAg specific CD8
+ T cells are potent
enough to break established immune tolerance and kill HBsAg
positive hepatocytes.
PZQ was previously shown in schistosomiasis patients to
significantly alter immune responses [25,26,36]. However, it was
not explored as an immune adjuvant until its recent demonstration
as an augmenting effect on cellular responses to DNA vaccination
[27]. As such, we have sought to further characterize this drug in
terms of the types of immune responses and subsets of T cells it
affects. To assess the effects of PZQ, DTH was utilized. In this
study, we demonstrated that PZQ induced a higher DTH
response than that of a DNA vaccine alone. Although Th1 and
Tc1 cells have been previously studied in detail to show their
associations with IFN-c dependent DTH responses, Th17 cells,
Tc17 and macrophages have also been demonstrated to involve
the induction of DTH as well [31,37,38]. During DNA
vaccination alone, the levels of DTH as showed in Fig. 3 had a
slight difference between KO and wild type mice, suggesting that
DTH could be derived from CMI other than Tc1 and Tc17 cells.
In the case of DNA vaccination with PZQ, however, Tc17 and
Tc1 were the main contributors for DTH. Therefore, the causes of
DTH could be due to a complicated mechanism.
Tc1 cells are the classical cytotoxic T cells that produce IFN-c
and TNF-a and can destroy virally infected cells through the
targeted secretion of perforin and granzymes from lytic granules
[39,40,41]. Tc17 cells, which produce IL-17 [42,43,44,45,46,47],
Figure 3. Impairment of DTH in IFN-c KO mice and IL-17 KO mice immunized with pcD-S2 and PZQ. Mice were challenged with rHBsAg
12 days after the second immunization. DTH was measured at 24, 48 and 72 h. A and B, DTH of IFN-c and IL-17 KO mice, respectively. Data shown are
representative of three independent experiments (* p,0.05; ns, p.0.05).
doi:10.1371/journal.pone.0025525.g003
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animal against acute influenza virus infection [48]. To date, HBV
specific Tc1 cells have been demonstrated to control chronic HBV
infection [7,15] and eliminate HBV infected hepatocytes in
transgenic animal model [19,20]. In contrast, the role of Tc17
cells in HBV protection is not understood. Our data show, for the
first time, that Tc17 cells kill HBsAg-positive hepatocytes in vivo.
This observation appears to suggest that, similar to Tc1, Tc17 cells
are essential effectors.
Although it has been demonstrated that Tc17 cells-mediated
cytolytic killing could support the anti-viral immunity through
recruiting neutrophils by IL-17 secretion, by secreting IFN-c,o r
by expressing FasL [12,42,48], our data demonstrated that these
IL-17-postive and IFN-c-negative Tc17 cells were involved in
antigen-specific cytotoxic responses that had capacity to kill
HBsAg-positive hepatocytes in vivo. These IL-17-producing Tc17
cells mediated the broad CTL mainly through a common cytolytic
or Fas-FasL as previous studies indicated [12,48]. In future
experiments, it will be determined if neutrophils are recruited and
infiltrated to the sites. As well, the expressions of FasL of Tc17 cells
will be analyzed.
The specific role of IL-17 involved in anti-viral immunity
remains elusive. It has been shown that blockade of IL-17 resulted
in diminishing the survival in response to lethal influenza virus
challenge [49], indicating that IL-17 may play some roles in the
anti-viral response and protection. IL-17 had been found to
participate in host defense against VV infection and recruit
neutrophils [50]. Tc17 cells could protect against acute viral
infection through recruiting neutrophils or through the secretion of
FasL [12,42,48]. Perhaps IL-17 could recruit or activate the innate
and adaptive immune cells against viral infection. Therefore, its
anti-viral role should be further investigated.
T cell-mediated cytolytic killing can result in tissue injury. Liver
injury was detected through the elevation of serum ALT, which
reached the highest level on week 1 post last immunization in
HBsAg-Tg mice and gradually declined to the basal level.
However, the extent of liver damage appeared to be limited, as
histology of the liver during the same time window revealed no
gross change in liver morphology. Therefore, specific killing of the
HBsAg positive cells may cause limited damage to the liver, but
not result in gross pathology. Further investigation is needed to
further clarify this point.
Figure 4. PZQ enhancement of the induction of Tc1 and Tc17 cells in HBsAg-transgenic mice. A, Splenic T cells were isolated on day 14
after the third immunization and stimulated with S208-215 in the presence of brefeldin A (5 mg/ml) for 6 h in culture. CD8
+ T cells were intracellularly
immunostained for IFN-c and IL-17. B, 12 days after the second immunization, DTH was measured at 24, 48 and 72 h later. Results were
representative of three independent experiments (* p,0.05).
doi:10.1371/journal.pone.0025525.g004
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change the level of HBsAg in serum. This disconnection has been
described in several previous publications. Particularly, it was
reported that therapeutic vaccination cleared chronic hepatitis B
virus and caused HBeAg seroconversion in chronic carrier
chimpanzees, with HBsAg remaining in serum throughout the
observation period [51]. Another report showed that the levels of
serum HBV DNA and HBeAg were decreased without HBsAg
seroconversion in patients [52]. Therefore, one could speculate
that a small proportion of HBsAg positive hepatocytes could
maintain the high concentration of HBsAg in the serum, resulting
in a mild decrease or clearance of HBsAg in the serum, even if a
large proportion of HBsAg positive cells are already cleared.
In summary, our results demonstrate ,for the first time, that a
HBsAg DNA vaccine, with PZQ, used as adjuvant can induce
both Tc1 and Tc17 in vivo and result in elimination of HBsAg
positive cells. Since PZQ is already an approved clinic drug, its use
for HBsAg DNA vaccination should be safe enough to advance to
clinical trials to further examine its potential as a human adjuvant.
A more general application of PZQ as a pro-Tc1 and Tc17
adjuvant may also be explored for other immunotherapeutic
vaccines to control other chronic viral infections.
Materials and Methods
Animals and reagents
Female C57BL/6 mice of 8–10 weeks of age were purchased
from the Animal Institute of Chinese Medical Academy
(Beijing, China). HBsAg-transgenic (Tg) mice (C57BL/6J-
Tg(Alb1HBV)44Bri/J) and IFN-c KO (B6.129S7-Ifng
tm1Ts/J)
mice were purchased from the Jackson Laboratory (Bar Harbor,
Maine). IL-17 KO mice (C57BL/6 background) were kindly
provided by Richard Flavell (Yale University School of Medicine,
New Haven, CT). All animal protocols (#28482) were approved
by the Animal Welfare Committee of China Agricultural
University and housed with pathogen-free food and water under
12 h light-cycle conditions.
Praziquantel (NCPC, Hebei, China) was initially dissolved in
ethanol to 6.7% and subsequently diluted to 0.5% with 0.9%
saline solution. The vehicle was 7.5% ethanol with 0.9% saline
Figure 5. Histopathology of the liver and serology assays. A: livers from each group were obtained on day 14 after the third immunization
and fixed, sectioned, and stained with H&E. Bar, 50 mm. CD8-specific immunostaining of the liver from HBsAg transgenic mice on day 14 after final
immunization. Bar, 20 mm. Specific immunostaining of HBsAg on day 14 after final immunization. Bar, 50 mm. B: Percentage of HBsAg-positive liver
cells in indicated groups on day 14 after final immunization. C: HBsAg antigen in the serum on day 14 after final immunization. D: ALT activity in the
serum on weeks 0, 1, 2, 3, and 4 after the third immunization. Results were representative of three independent experiments. There were four mice in
each group (* p,0.05; ns, p.0.05).
doi:10.1371/journal.pone.0025525.g005
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kindly provided by China North Pharmaceutical Group Corpo-
ration (NCPC, Hebei, China). The HBsAg-derived peptides S208-
215 (ILSPFLPL; H-2K
b-restricted) were synthesized by GL
BiochemCo., Ltd. (Shanghai, China). Rat anti-mouse CD4 mAb
(GK1.5), Rat anti-mouse CD8 mAb (53-6.7) and rat IgG were
purchased from eBioscience (San Diego, CA, USA). Fluorescent-
labeled anti-mouse mAbs including anti-CD4-FITC, anti-CD8-
FITC, anti-CD8-APC, anti-IFN-c-PE, anti- IL-17-PE and anti-IL-
17-APC were purchased from BD PharMingen (San Diego, CA,
USA). The anti-HBsAg antibody for immunohistochemical
staining was produced in C57BL/6 mice immunized 3 times with
rHBsAg and alum as adjuvant.
Plasmid construction and preparation
For mouse studies, the HBV DNA vaccine (pcD-S2) was prepared
as described previously [27]. The plasmid was maxi-prepared by the
alkaline method, subsequently purified by Qiagen Maxi prep kit
(Qiagen Inc., Duesseldorf, Germany), and diluted in saline solution.
Immunization
Mice were randomly divided into six or seven groups (n=6
each) according to the design of different experiments, and were
immunized with 100 mg pcD-S2 per mouse [27]. pcD was the
empty vector for pcDNA3. All mice were immunized on day 0 and
boosted on day 14.
Elicitation of delayed-type of hypersensitivity (DTH)
Twelve days after the second immunization, all groups were
challenged with 10 mg of rHBsAg in the right footpad as test and
saline solution at the left footpad as control. The thicknesses of
footpads were measured at 24, 48 and 72 h with a micrometer and
calculated using the following formula: thickness footpad=thick-
ness of right footpad - thickness of left footpad.
For elimination of CD4
+ and CD8
+ T cells, anti-CD4 mAb
(200 mg/mouse), anti-CD8 mAb (200 mg/mouse), or rat IgG
(200 mg/mouse) was injected (i.p.) twice into immunized mice on
days 10 and 11 after the second immunization. The mice were
challenged on day12 and DTH was measured as described above.
Flow cytometry
Splenic cells were isolated on day 7 after the final immunization
and stimulated with 10 mg/ml S208-215 in the presence of
brefeldin A (5 mg/ml) for 6 h at 37uC and 5% CO2. Collected cells
were fixed with 4% paraformaldehyde and permeabilized with
0.1% saponin (Sigma-Aldrich). For immunostaining of cytoplas-
Figure 6. Adoptive transfer of PZQ-induced CD8
+ T cells. A: In vivo cytotoxic lysis was performed in the wild type, IFN-c KO and IL-17 KO mice
on day 7 after the third immunization with pcD-S2 and PZQ. B: The percentage of specific lysis was summarized. C: HBsAg-specific immunostaining of
HBsAg of livers from the HBsAg transgenic mice was analyzed on day 14 after adoptive transfer. Bar, 20 mm. D: Percentage of HBsAg-positive liver
cells. E, ALT level in the serum was detected on weeks 0, 1 and 2 after adoptive transfer of CD8
+ T cells. The data shown are representative of three
independent experiments (* p,0.05; ** p,0.01; ns, p.0.05).
doi:10.1371/journal.pone.0025525.g006
PZQ Primes Tc1 and Tc17
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concentrations of fluorescently labeled anti-mouse monoclonal
antibodies were added to permeabilized cells for 30 min on ice
followed by washing twice with cold PBS. Samples were analyzed
by a FACSCalibur.
Histopathology
On day 7 after final immunization, liver tissue was paraffin-
embedded, sectioned, stained with H&E, and immunostained with
anti-HBsAg mAb, anti-CD4 mAb, or anti-CD8 mAb. Analysis was
performed under a light microscope for histological changes.
In vivo cytotoxic assay
Splenocytes from naı ¨ve C57BL/6 mice were pulsed with
10
26 M HBsAg-derived peptides S208-215 and labeled with a
high concentration of CFSE (15 mM, CFSE
high cells) as target cells.
A portion of the same splenocytes was labeled with a low
concentration of CFSE (0.5 mM, CFSE
low cells) without peptide
pulse as a non-target control. The target and control cells were
mixed in a 1:1 ratio and injected into immunized mice at 2610
7
total cells per mouse via the tail vein on day 7 after the third
immunization. Eight hours later lymphnodes and the spleen of
injected mice were removed and the target and control cells were
analyzed by their differential CFSE fluorescent intensities using a
FACSCalibur (BD Biosciences, USA). Specific lysis was calculated
using the following formula: Percentage specific lysis=[12
(ratio unprimed/ratio primed)6100], where ratio=percentage
CFSE
low/percentage CFSE
high.
Adoptive transfer of CD8
+ T cells
On day 7 after the third immnuzation with pcD-S2 and PZQ,
single-splenocyte suspensions were prepared from spleen of wild
type, IFN-c KO or IL-17KO mice. CD8
+ T cells were isolated
and purified using the MagCellect Mouse CD8
+ T Cell Isolation
Kit according to the manufacturer’s protocol (R&D Systems, Inc.,
Minneapolis, USA). Purity of each cell preparation was 90–95%.
The cells were adoptively transferred intravenously into normal
HBsAg transgenic mice at 5610
6 per recipient mouse.
Statistical analysis
Pairwise differences were analyzed by the two-sided Student’s t
test. For multi-group analysis, ANOVA and the Bonferroni test
were used. A value of p,0.05 was considered to be statistically
significant.
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